Not losing weight on 7.5mg Mounjaro: what's actually happening

Is a plateau at 7.5mg actually unusual?

Probably not. The SURMOUNT-1 trial (which followed thousands of adults over 72 weeks) showed that weight loss on tirzepatide tends to taper between escalation steps before picking up again at the next dose. The biggest reductions were seen over the full treatment period at higher doses, not at any single mid-point. Expecting linear, week-on-week loss at every stage sets a target the data doesn't support.

The body also adapts. After weeks at a new dose level, hunger signals begin to recalibrate and appetite suppression can feel less pronounced than it did in the first week or two. That's a physiological response, not a sign that the medicine has stopped working. If you've recently moved up from 5mg, it's also worth reading about why weight loss can stall at that earlier stage, since the same underlying patterns often carry forward into the 7.5mg phase.

A quick check worth doing right now: pull up the last four weeks of your injection dates and confirm the timing has been consistent. Missing a dose by more than a day or two, or accidentally injecting at irregular intervals, blunts the steady-state effect that tirzepatide relies on. Takes under a minute and it's often the first thing a prescriber asks about.

Could the dose itself be the issue, and is 7.5mg where you should stay?

7.5mg is the third step on the licensed titration schedule, which starts at 2.5mg and escalates in 2.5mg increments. It is not a plateau destination for most people; it's a waypoint. The licensed schedule continues to 10mg, 12.5mg and 15mg. The NICE appraisal of tirzepatide (TA1026) assessed evidence at the full range of doses, and the most substantial average weight reductions were recorded at the higher end of the schedule, around 20–21% of body weight at 15mg in SURMOUNT-1, compared to more modest figures at earlier steps.

This doesn't mean everyone should push to 15mg regardless of side effects or clinical picture. But it does mean that if 7.5mg has been well tolerated and weight loss has stalled for more than a few weeks, the titration conversation with your prescriber is a reasonable next step. You can read more about what the therapeutic dose range means clinically and how prescribers approach it.

For context on what the earlier experience looks like at lower doses, the 7.5mg stall is a closely related scenario many patients find useful to read through alongside the 2.5mg experience, since the underlying factors that slow progress often appear at multiple points across the titration schedule.

What non-dose factors could be slowing things down?

Tirzepatide works by reducing appetite and slowing gastric emptying, which creates the conditions for a calorie deficit. It does not create that deficit automatically regardless of what you eat. If appetite suppression is working but food choices haven't shifted, the deficit may not be as large as expected. Ultra-processed foods, liquid calories and irregular meal timing can all partially offset the medicine's effect, not because the drug is failing, but because the gap between intake and expenditure is narrower than it looks.

Sleep is another underappreciated variable. Poor sleep raises ghrelin (the hunger hormone) and lowers the satiety signals that tirzepatide is partly working through. Stress has a similar profile. Neither is easy to fix quickly, but they're worth flagging in a prescriber review.

Activity matters too, and not only for calorie burn. Resistance training in particular helps preserve lean muscle mass during weight loss, which matters for long-term metabolic rate. The NHS guidance on maintaining a healthy weight covers the lifestyle components that sit alongside any medical treatment. These aren't extras, they're part of how the medicine performs at its best.

When should you actually speak to a prescriber?

If you've been on 7.5mg for four weeks or more, injection timing has been consistent, lifestyle factors are broadly in order and the scale has not moved at all, that is the right moment to ask for a clinical review. A prescriber can assess whether a dose increase is appropriate, whether something in your medical history or other medicines could be affecting response, and whether the titration schedule needs adjusting.

At nume, every repeat order is reviewed by a GPhC-registered prescriber before it's approved. If you want to discuss how things are going at 7.5mg specifically, our team is available seven days a week for aftercare queries. You can also read through our frequently asked questions for common clinical questions answered by our prescribers, or explore the broader picture of how Mounjaro works across the full treatment journey.

If you're not yet a patient and want a clinical assessment of whether Mounjaro is appropriate for you at this stage, the right starting point is a free consultation with our prescribers, every assessment is done the same day by a named clinician, not software.